HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat

Histone deacetylases (HDAC) are key players in epigenetic regulation of gene expression and HDAC inhibitor (HDACi) treatment seems to be a promising anticancer therapy in many human tumours, including soft tissue sarcomas. HR23b has been shown to be a potential biomarker for sensitivity to HDACi the...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Pathol Clin Res
Главные авторы: Angelika Ihle, Michaela, Merkelbach‐Bruse, Sabine, Hartmann, Wolfgang, Bauer, Sebastian, Ratner, Nancy, Sonobe, Hiroshi, Nishio, Jun, Larsson, Olle, Åman, Pierre, Pedeutour, Florence, Taguchi, Takahiro, Wardelmann, Eva, Buettner, Reinhard, Schildhaus, Hans‐Ulrich
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2016
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907056/
https://ncbi.nlm.nih.gov/pubmed/27499916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cjp2.35
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы